Evidence map›Paper›PMID 42486979›Full record

ArticleNature2026

Tertiary lymphoid structures harbour stem-like tumour-specific T cells.

Alexander B Afeyan, Adi Nagler, Chloe R Tu, Gabriel Roberti De Oliveira, Berkay Simsek, Maxwell D Seager, Nourhan El Ahmar, Haley E Sax, Emma Lin, Amit Sud and 18 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Epigenetic plus cytokine therapy induces stem-like CD8Journal for immunotherapy of cancer · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Alexander B Afeyan *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0525-7166
Adi Nagler *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Chloe R Tu *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gabriel Roberti De OliveiraDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0009-0008-6565-7720
Berkay SimsekDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Maxwell D SeagerDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0009-0009-1111-6854
Nourhan El AhmarDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Haley E SaxDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0000-9277-086X
Emma LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0005-0560-2849
Amit SudDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6133-0164
Mehdi BorjiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Cleo FormanDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Sophia LiuBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3614-9731
Patrick A OttDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4253-943X
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9201-3217
Jennifer G AbelinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5262-7241
Richard BurackUniversity of Rochester Medical Center, Department of Pathology and Laboratory Medicine, Rochester, NY, USA.ORCID http://orcid.org/0000-0002-5584-584X
Shuqiang LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9106-6141
Kenneth J LivakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9105-5856
Svitlana TyekuchevaDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Derin B KeskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Fei ChenBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-2308-3649
Michael B AtkinsGeorgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.ORCID http://orcid.org/0000-0003-3901-9924
Jeremy M SimonDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3906-1663
Sabina SignorettiHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5000-9105
Giacomo OliveiraDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. giacomo_oliveira@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-7435-5603
David A BraunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. david.braun@yale.edu.ORCID http://orcid.org/0000-0003-4543-5553
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. catherine_wu@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-3348-5054

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tertiary lymphoid structures (TLSs) are associated with improved responses to immune checkpoint blockade across solid tumours

Indexed as

Carcinoma, Renal CellCD8-Positive T-LymphocytesKidney NeoplasmsNeoplastic Stem CellsTertiary Lymphoid StructuresAnimalsClone CellsFemaleHumansMacrophagesReceptors, Antigen, T-CellT-Cell ExhaustionTumor EscapeTumor MicroenvironmentReceptors, Antigen, T-Cell

Identifiers

PMID42486979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.